Accuray Incorporated — Form 10-Q Summary
Business context and reporting period
Accuray develops and sells CyberKnife radiosurgery and TomoTherapy radiation therapy systems, related upgrades, and services. This filing covers the three months ended September 30, 2015—the company’s first quarter of fiscal 2016, although the request metadata labels it “2015 Q1.” Comparisons are with the three months ended September 30, 2014. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Quarter ended Sep. 30, 2015 | Prior-year quarter |
|---|---|---|
| Revenue | $89.6 million | $82.4 million |
| Gross profit / gross margin | $33.9 million / 37.8% | $27.8 million / 33.7% |
| Operating loss | $7.2 million | $15.3 million |
| Net loss | $13.0 million; $0.16 per share | $21.7 million; $0.28 per share |
| Operating cash flow | $12.3 million provided | $14.7 million used |
| Capital expenditures | $1.5 million | $2.7 million |
Product revenue rose 21% to $40.0 million; services revenue was nearly flat at $49.6 million. Cash and cash equivalents were $85.6 million and short-term investments were $67.5 million at September 30, for combined liquidity of $153.1 million. Restricted cash was an additional $3.8 million. Current assets were $350.7 million and current liabilities $263.3 million. Management said available cash, investments, and expected cash flows should fund operations for at least 12 months.
Debt carrying value totaled $204.8 million ($215.0 million principal). Of the carrying value, $95.1 million was classified as short-term, principally the 3.75% convertible notes due August 2016; $109.6 million was long-term. The filing reports total liabilities of $397.7 million.
Material changes versus the prior-year quarter
- Revenue increased 9%; higher system sales and demand for CyberKnife MLC upgrades contributed to product growth.
- Gross profit increased 22%, with product margin rising to 42% from 37% and service margin to 34% from 31%. Management attributed improvement to more systems recognized, fixed-cost leverage, and lower service costs.
- Selling and marketing expense fell 25% to $13.4 million, partly because ASTRO trade-show costs shifted to the following quarter. General and administrative expense rose 23% to $13.4 million, largely reflecting legal costs and the Cowealth award.
- Operating cash flow improved from use of $14.7 million to provision of $12.3 million. Collections drove a $20.9 million decrease in accounts receivable, while inventory increased $7.2 million.
- Product backlog was $379.8 million, up from $364.0 million a year earlier. Gross orders were $64.9 million versus $58.8 million; net orders were $44.8 million versus $32.3 million. Management attributed part of net-order growth to favorable foreign currency effects.
Outlook, commentary, risks, and unusual items
- Management expected fiscal 2016 second-quarter age-outs of $15 million to $19 million, broadly consistent with the prior-year period. It said changes to distributor oversight and order-entry processes are intended to improve backlog quality and reduce age-outs.
- Backlog is not a GAAP measure or a reliable predictor of revenue; cancellations, age-outs, customer construction and financing delays, regulatory approvals, and currency movements can affect conversion.
- The InCise MLC was commercially launched in fiscal 2015’s third quarter. Management identified continued adoption and reliable production and shipment as factors affecting CyberKnife growth.
- On October 29, 2015, the ICC awarded Cowealth approximately $3.4 million, denied injunctive relief, and ruled in Accuray’s favor on several counterclaims. Accuray recorded a $3.4 million charge in the September quarter; interest accrues at 5% annually beginning 30 days after the award. A separate legal-cost ruling remained pending, with no additional amount accrued.
- Other material risks include the August 2016 convertible-note maturity and refinancing needs, ongoing losses, dependence on reimbursement and customer capital spending, quarterly sales volatility, foreign-exchange exposure, and concentration of revenue: one customer represented 15% of quarterly revenue and 17% of receivables at quarter-end.
- The company reported no material change in contractual obligations outside the ordinary course, no off-balance-sheet arrangements, and effective disclosure controls as of September 30, 2015. No specific earnings or revenue guidance was provided.
Important facts for investors to verify
- How Accuray plans to repay, refinance, or otherwise address the $95.1 million short-term debt carrying value due principally in August 2016.
- Whether backlog converts to revenue as expected, including actual cancellations, age-outs, and customer installation delays.
- The final legal-cost outcome in the Cowealth arbitration and any resulting additional expense or cash payment.
- Whether operating cash generation is sustainable after accounting for inventory needs, debt obligations, and continuing net losses.
- Whether CyberKnife MLC adoption, product margins, and reimbursement conditions support continued growth.